RU2002123050A

RU2002123050A - New compounds, their preparation and use

Info

Publication number: RU2002123050A
Application number: RU2002123050/04A
Authority: RU
Inventors: Йохн Патрик МОГЕНСЕН (DK); Йохн Патрик Могенсен; Пер САУЕРБЕРГ (DK); Пер Сауерберг; Пол Стенли БЕРИ (GB); Пол Стенли БЕРИ; Лоне ЙЕППЕСЕН (DK); Лоне ЙЕППЕСЕН; Ингрид ПЕТТЕРССОН (DK); Ингрид Петтерссон
Original assignee: Ново Нордиск А/С (DK); Ново Нордиск А/С
Priority date: 2000-01-28
Filing date: 2001-01-26
Publication date: 2004-01-10

Claims

1. The compound of formula (I)

where X represents hydrogen, or

X represents C _1-12 alkyl, C _2-12 alkenyl, C _2-12 alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl or heterocyclyl, each of which is optionally substituted with one or more substituents selected from halogen, perhalogenomethyl, hydroxy, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, hydroxy, C _1-6 alkoxy, C _1-6 alkylthio, aryl, aryloxy, arylthio, acyl, aralkyl, aralkoxy , heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, C _1-6 alkylthio, cyano, amino, C _1-6 alkylamino, C _1-6 dialkylamino, carboxy or a C _1-6 alkyl ester; and

Y represents hydrogen, or

Y represents C _1-12 alkyl, C _2-12 alkenyl, C _2-12 alkynyl, C _4-12 alkenyl, aryl, heteroaryl, aralkyl, heteroalkyl, each of which is optionally substituted with one or more substituents selected from halogen, C _1-6 alkyl, perhalogenomethyl, hydroxy, aryl, heteroaryl, amino, carboxy or a C _1-6 alkyl ester; and

Z represents hydrogen, halogen, hydroxy, or

Z is C _1-6 alkyl or C _1-6 alkoxy, each of which is optionally substituted with one or more substituents selected from C _1-6 alkoxy, halogen, hydroxy, carboxy, amino or cyano; and

Q represents O, S or NR ₅ , where R ₅ represents hydrogen, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _4-6 alkenyl, aralkyl or heteroalkyl, and where R _{5 is} optionally substituted with one or more substituents selected from halogen, hydroxy, C _1-6 alkoxy, amino or carboxy; and

Ar represents an arylene, heteroarylene or divalent heterocyclic group, each of which may be optionally substituted with one or more substituents selected from C _1-6 alkyl, aryl or C _1-6 alkoxy, each of which may be optionally substituted with halogen, hydroxy, carboxy, or C _1-6 alkyl ester; and

R ₁ represents hydrogen, hydroxy or halogen; or R ₁ forms a bond with R ₂ ; and

R ₂ represents hydrogen or C _1-6 alkyl; or R ₂ forms a bond with R ₁ ; and

R ₃ represents hydrogen, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _4-6 alkenyl, aryl, aralkyl, C _1-6 alkoxy C _1-6 - alkyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl, optionally substituted with one or more substituents selected from halogen, perhalogenomethyl, hydroxy, cyano, carboxy or a C _1-6 alkyl ester; and

R ₄ represents hydrogen, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _4-6 alkenyl or aryl;

n is an integer from 0 to 3; and

m is an integer from 0 to 1;

or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate, or any tautomeric forms, stereoisomers, mixtures of stereoisomers, including a racemic mixture, or polymorphs.

2. The compound according to claim 1 of formula (I)

where X is hydrogen, or X is C _1-12 alkyl, C _2-12 alkenyl, C _2-12 alkynyl, aryl, heteroaryl, aralkyl, heteroalkyl or heterocyclyl, each of which is optionally substituted with one or more substituents selected from halogen, perhalogenomethyl, hydroxy, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, hydroxy, C _1-6 alkoxy, C _1-6 alkylthio, aryl, aryloxy, arylthio, acyl, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, C _1-6 alkylthio, cyano, amino, C _1-6 alkylamino, C _1-6 dialkylamino, carboxy si or C _1-6 alkyl ester; and

Y is hydrogen, or Y is C _1-12 alkyl, C _2-12 alkenyl, C _2-12 alkynyl, C _4-12 alkenyl, aryl, heteroaryl, aralkyl, heteroalkyl, each of which is optionally substituted one or more substituents selected from halogen, C _1-6 alkyl, perhalogenmethyl, hydroxy, aryl, heteroaryl, amino, carboxy or a C _1-6 alkyl ester; and

Z is hydrogen, halogen, hydroxy, or Z is C _1-6 alkyl or C _1-6 alkoxy, each of which is optionally substituted with one or more substituents selected from C _1-6 alkoxy, halogen, hydroxy, carboxy, amino or cyano; and

Q is O, S or NR ₅ , where R ₅ is hydrogen, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _4-6 alkenyl, aralkyl or heteroalkyl, and wherein R _{5 is} optionally substituted with one or more substituents selected from halogen, hydroxy, C _1-6 alkoxy, amino or carboxy; and

R ₃ represents hydrogen, C _1-6 alkyl, C _1-6 alkenyl, C _2-6 alkynyl, C _4-6 alkenyl, aryl, aralkyl, C _1-6 alkoxy C _1-6 - alkyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl, optionally substituted with one or more substituents selected from halogen, perhalogenomethyl, hydroxy, cyano, carboxy or a C _1-6 alkyl ester; and

n is an integer from 1 to 3; and

m is 1;

3. The compound according to any one of the preceding claims

where X represents hydrogen, C _1-12 alkyl, C _2-12 alkenyl, C _2-12 alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl or heterocyclyl, optionally substituted with one or more substituents selected from halogen, perhalogenomethyl, hydroxy, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, hydroxy, C _1-6 alkoxy, C _1-6 alkylthio, aryl, aryloxy, arylthio, acyl, aralkyl, aralkoxy , heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, C _1-6 alkylthio, cyano, amino, C _1-6 alkylamino, C _1-6 dialkylamino, carboxy or a C _1-6 alkyl ester; and

Y represents hydrogen, C ₁ - ₁₂ -alkyl, C _2-12 -alkenyl, C _2-12 -alkynyl, C _4-12 -alkeninil, aryl, heteroaryl, aralkyl, heteroaralkyl, optionally substituted by one or more substituents selected from halogen, C _1-6 alkyl, perhalogenomethyl, hydroxy, aryl, heteroaryl, amino, carboxy or a C _1-6 alkyl ester; and

Z is hydrogen, halogen, hydroxy, C _1-6 alkyl or C _1-6 alkoxy optionally substituted with one or more substituents selected from C _1-6 alkoxy, halogen, hydroxy, carboxy, amino or cyano; and

Q is O, S or NR ₅ , where R ₅ is hydrogen, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _4-6 alkenyl, aralkyl or heteroalkyl, and where R _{5 is} optionally substituted with one or more substituents selected from halogen, hydroxy, C _1-6 alkoxy, amino or carboxy; and

R ₃ represents hydrogen, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _4-6 alkenyl, aryl, aralkyl, C _1-6 alkoxy-C _1-6 - alkyl, acyl, heterocyclyl, heteroaryl or heteroalkyl optionally substituted with one or more substituents selected from halogen, perhalogenomethyl, hydroxy, cyano, carboxyl or a C _1-6 alkyl ester; and

n is an integer from 0 to 3; and

m is an integer from 0 to 1;

4. The compound according to any one of the preceding paragraphs, where X is aryl, heteroaryl or heterocyclyl, optionally substituted with one or more substituents selected from halogen, perhalogenmethyl, C _1-6 alkoxy, C _1-6 alkylthio, aryl, aryloxy, arylthio, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.

5. The compound according to any one of the preceding paragraphs, where X is aryl, heteroaryl or heterocyclyl, each of which is optionally substituted with one or more substituents selected from halogen, perhalogenmethyl, C _1-6 alkoxy, C _1-6 alkylthio, aryl , aryloxy, arylthio, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.

6. The compound according to any one of the preceding paragraphs, where X is aryl, optionally substituted with one or more substituents selected from halogen, perhalogenomethyl, C _1-6 alkoxy, C _1-6 alkylthio, aryl, aryloxy, arylthio, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.

7. The compound according to any one of the preceding paragraphs, where X is phenyl or naphthyl, each of which is optionally substituted with one or more substituents selected from halogen or perhalogenmethyl.

8. The compound according to any one of the preceding paragraphs, where X is phenyl, optionally substituted with one or more substituents selected from halogen.

9. The compound according to any one of the preceding paragraphs, where X is phenyl.

10. The compound according to any one of the preceding paragraphs, where X is heteroaryl, optionally substituted with one or more substituents selected from halogen, perhalogenomethyl, C _1-6 alkoxy, C _1-6 alkylthio, aryl, aryloxy, arylthio, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.

11. The compound according to any one of the preceding paragraphs, where X is heterocyclyl, optionally substituted with one or more substituents selected from halogen, perhalogenomethyl, C _1-6 alkoxy, C _1-6 alkylthio, aryl, aryloxy, arylthio, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.

12. The compound according to any one of the preceding paragraphs, where Y represents hydrogen, C _1-12 -alkyl or aryl.

13. The compound according to any one of the preceding paragraphs, where Y is hydrogen or methyl.

14. The compound according to any one of the preceding paragraphs, where Y represents hydrogen.

15. The compound according to any one of the preceding paragraphs, where Z represents hydrogen or C _1-6 alkoxy.

16. The compound according to any one of the preceding paragraphs, where Z represents hydrogen.

17. The compound according to any one of the preceding paragraphs, where Q is O.

18. The compound according to any one of the preceding paragraphs, wherein Ar is arylene optionally substituted with one or more substituents selected from C _1-6 alkyl or C _1-6 alkoxy, each of which may optionally be substituted with carboxy.

19. The compound according to any one of the preceding paragraphs, where Ar is phenylene.

20. The compound according to any one of the preceding paragraphs, where R ₁ represents hydrogen or R ₁ forms a bond with R ₂ .

21. The compound according to any one of the preceding paragraphs, where R ₁ represents hydrogen.

22. The compound according to any one of the preceding paragraphs, where R ₂ represents hydrogen or R ₂ forms a bond with R ₁ .

23. The compound according to any one of the preceding paragraphs, where R ₂ represents hydrogen.

24. The compound according to any one of the preceding paragraphs, where R ₃ represents a C _1-6 -alkyl.

25. The compound according to any one of the preceding paragraphs, where R ₃ represents a C _1-2 alkyl.

26. The compound according to any one of the preceding paragraphs, where R ₄ represents hydrogen.

27. The compound according to any one of the preceding paragraphs, where n is 1.

28. The compound according to any one of the preceding paragraphs, where m is 1.

29. The compound according to any one of the preceding paragraphs, where the substituents Z and Y are located in a trans configuration.

30. The compound according to any one of the preceding paragraphs, where the substituents Z and Y are located in the cis configuration.

31. The compound according to claim 1, 2 or 3, which is:

(E) - (S) -2-ethoxy-3- [4- (5-phenylpent-2-en-4-ynyloxy) phenyl] propionic acid ethyl ester,

(E) - (S) -2-ethoxy-3- [4- (5-phenylpent-2-en-4-ynloxy) phenyl] propionic acid,

(Z) - (S) -2-ethoxy-3- [4- (3-methyl-5-phenylpent-2-en-4-ynyloxy) phenyl] propionic acid ethyl ester,

(Z) - (S) -2-ethoxy-3- [4- (3-methyl-5-phenylpent-2-en-4-ynyloxy) phenyl] propionic acid,

(E) - (S) -2-ethoxy-3- [4- (3-methyl-5-phenylpent-2-en-4-ynyloxy) phenyl] propionic acid ethyl ester,

(E) - (S) -2-ethoxy-3- [4- (3-methyl-5-phenylpent-2-en-4-ynyloxy) phenyl] propionic acid,

or a pharmaceutically acceptable salt thereof.

32. The compound according to claim 1, 2 or 3, which is:

ethyl (E) - (S) -2-ethoxy-3- [4- (3-methyl-5- (3,5-dichlorophenyl) pent-2-en-4-ynyloxy) phenyl] propionate,

(E) - (S) -2-ethoxy-3- [4- (3-methyl-5- (3,5-dichlorophenyl) pent-2-en-4-ynyloxy) phenyl] propionic acid,

ethyl- (Z) - (S) -2-ethoxy-3- [4- (3-methyl-5- (3,5-dichlorophenyl) pent-2-en-4-ynyloxy) phenyl] propionate,

(Z) - (S) -2-ethoxy-3- [4- (3-methyl-5- (3,5-dichlorophenyl) pent-2-en-4-ynyloxy) phenyl] propionic acid,

ethyl (E) - (S) -2-ethoxy-3- [4- (3-methyl-5- (3-trifluoromethylphenyl) pent-2-en-4-ynyloxy) phenyl] propionate,

(E) - (S) -2-ethoxy-3- [4- (3-methyl-5- (3-trifluoromethylphenyl) pent-2-en-4-ynyloxy) phenyl] propionic acid,

ethyl (Z) - (S) -2-ethoxy-3- [4- (3-methyl-5- (3-trifluoromethylphenyl) pent-2-en-4-ynyloxy) phenyl] propionate,

(Z) - (S) -2-ethoxy-3- [4- (3-methyl-5- (3-trifluoromethylphenyl) pent-2-en-4-ynyloxy) phenyl] propionic acid,

or a pharmaceutically acceptable salt thereof.

33. The compound according to claim 1, 2 or 3, which is:

ethyl (E) - (S) -2-ethoxy-3- [4- (3-methyl-5- (1-naphthyl) pent-2-en-4-ynyloxy) phenyl] propionate,

(E) - (S) -2-ethoxy-3- [4- (3-methyl-5- (1-naphthyl) pent-2-en-4-ynyloxy) phenyl] propionic acid,

ethyl- (Z) - (S) -2-ethoxy-3- [4- (3-methyl-5- (1-naphthyl) pent-2-en-4-ynyloxy) phenyl] propionate,

(Z) - (S) -2-ethoxy-3- [4- (3-methyl-5- (1-naphthyl) pent-2-en-4-ynyloxy) phenyl] propionic acid,

ethyl (E) - (S) -2-ethoxy-3- [4 - (- 5- (3,5-dichlorophenyl) pent-2-en-4-ynyloxy) phenyl] propionate,

(E) - (S) -2-ethoxy-3- [4- (5- (3,5-dichlorophenyl) pent-2-en-4-ynyloxy) phenyl] propionic acid,

or a pharmaceutically acceptable salt thereof.

34. The compound according to claim 1, 2 or 3, which is:

(Z) - (S) -2-ethoxy-3- [4- (5-phenylpent-2-en-4-ynyloxy) phenyl] propionic acid ethyl ester,

(Z) - (S) -2-ethoxy-3- [4- (5-phenylpent-2-en-4-ynloxy) phenyl] propionic acid,

(E) - (RS) -2-ethoxy-3- [3- (5-phenylpent-2-en-4-ynyloxy) phenyl] propionic acid ethyl ester;

or a pharmaceutically acceptable salt thereof.

35. The compound according to claim 1, 2 or 3, which is:

(E) - (S) -3- {4- [5- (1,3-difluorophenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-dibromophenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-diiodophenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] phenyl) -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-diethoxyphenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid

(E) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid

(E) - (S) -3- {4- [5- (3,5-difluorophenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dibromophenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diiodophenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diethoxyphenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid

(E) - (S) -3- {4- [5- (1,3-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] phenyl} -3-methyl-2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2 ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} - 2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} - 2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} - 2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1, 3-difluorophenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-dibromophenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-diiodophenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-diethoxyphenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} - 2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} - 2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-difluorophenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dibromophenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diiodophenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diethoxyphenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} - 2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} - 2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl) -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -3-methyl-2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl) -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- chlorophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-difluorophenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-dibromophenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-diiodophenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-diethoxyphenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} - 2-ethoxypropionic acid,

(E) (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2 ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-difluorophenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dibromophenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diiodophenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diethoxyphenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} - 2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} - 2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -3-methyl-2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- bromophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-difluorophenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-dibromophenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-diiodophenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-diethoxyphenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2 ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} - 2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-difluorophenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dibromophenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diiodophenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diethoxyphenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} - 2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} - 2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- {1,3-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) (S) -3- {4- [5- (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -3-methyl-2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- iodophenyl} -2-ethoxypropionic acid,

(E) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- iodophenyl} -2-ethoxypropionic acid,

or a pharmaceutically acceptable salt thereof.

36. The compound according to claim 1, 2 or 3, which is:

(Z) - (S) -3- {4- [5- (1,3-difluorophenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5 (1,3-dibromophenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diiodophenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diethoxyphenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid

(Z) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid

(Z) - (S) -3- {4- [5- (3,5-difluorophenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dibromophenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diiodophenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diethoxyphenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid

(Z) - (S) -3- {4- [5- (1,3-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] phenyl} -3-methyl-2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} - 2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} - 2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} - 2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] phenyl} - 2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-difluorophenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-dibromophenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diiodophenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diethoxyphenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} - 2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} - 2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-difluorophenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dibromophenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diiodophenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diethoxyphenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} - 2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} - 2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-chlorophenyl} -3-methyl-2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4 [5 (3,5-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- chlorophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-difluorophenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-dibromophenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diiodophenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diethoxyphenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} - 2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5 (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2 ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-difluorophenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dibromophenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diiodophenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diethoxyphenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} - 2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} - 2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-bromophenyl} -3-methyl-2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- bromophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-difluorophenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-dibromophenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diiodophenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5 (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diethoxyphenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} - 2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} - 2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-difluorophenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dibromophenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diiodophenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis-trifluoromethylphenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diethoxyphenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} - 2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} - 2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-dimethoxyphenyl) pent-2-en-4-ynyloxy] -3-iodophenyl} -3-methyl-2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (1,3-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-difluorophenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dibromophenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diiodophenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis-trifluoromethylphenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-dimethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-diethoxyphenyl) -3-methylpent-2-en-4-ynyloxy] -3-iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoromethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- iodophenyl} -2-ethoxypropionic acid,

(Z) - (S) -3- {4- [5- (3,5-bis- (2,2,2-trifluoroethoxy) phenyl) -3-methylpent-2-en-4-ynyloxy] -3- iodophenyl} -2-ethoxypropionic acid,

or a pharmaceutically acceptable salt thereof.

37. A pharmaceutical composition comprising a compound according to any one of the preceding claims or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent.

38. The composition according to clause 37 in the form of a standard dosage form containing from about 0.05 to about 100 mg, preferably from about 0.1 to about 50 mg, the compound according to any one of the preceding paragraphs or its pharmaceutically acceptable salt.

39. A pharmaceutical composition for treating and / or preventing conditions mediated by nuclear receptors, in particular receptors activated by peroxisomal proliferation factor (PPAR), wherein the composition contains, as an active ingredient, the compound according to any one of the preceding paragraphs or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

40. A pharmaceutical composition for treating and / or preventing diabetes and / or obesity, wherein the composition comprises, as an active ingredient, a compound according to any one of the preceding claims or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

41. The pharmaceutical composition according to any one of claims 37-40 for oral, nasal, transdermal, intrapulmonary or parenteral administration.

42. A method of treating ailments, comprising administering to a subject in need thereof an effective amount of a compound according to any one of the preceding claims or a pharmaceutically acceptable salt thereof, or a composition according to any one of the preceding claims 37-41.

43. A method of treating and / or preventing conditions mediated by nuclear receptors, in particular receptors activated by peroxisomal proliferation factor (PPAR), comprising administering to a subject in need thereof an effective amount of a compound according to any one of the preceding paragraphs or a pharmaceutically acceptable salt or composition thereof according to any from the preceding paragraphs. 37-41.

44. A method of treating and / or preventing diabetes and / or obesity, comprising administering to a subject in need thereof an effective amount of a compound according to any one of the preceding paragraphs or a pharmaceutically acceptable salt thereof, or a composition according to any one of the preceding claims 37-41.

45. The method according to § 42, 43 or 44, where the effective amount of the compound according to any one of the preceding paragraphs or its pharmaceutically acceptable salt or ester is from about 0.05 to about 100 mg per day, preferably from about 0.1 up to about 50 mg per day.

46. The use of a compound according to any one of the preceding claims or a pharmaceutically acceptable salt thereof for the manufacture of a medicament.

47. The use of a compound according to any one of the preceding claims or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment and / or prophylaxis of conditions mediated by nuclear receptors, in particular peroxisomal proliferation factor (PPAR) activated receptors.

48. The use of a compound according to any one of the preceding claims or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment and / or prevention of diabetes and / or obesity.

49. A method of obtaining a compound of formula I, which includes the interaction of the compounds of formula IV

where X, Y, Z are defined in claim 1 and t is 0-2, with a compound of formula V

where Q, Ar, R ₁ , R ₂ , R ₃ , R ₄ and m are defined in claim 1, except that m is not 0, under Mitsunobu conditions, using a reagent such as triphenylphosphine / diethyl azodicarboxylate and the like, to obtain a compound of formula I, where X, Y, Z, Q, Ar, R ₁ , R ₂ , R ₃ , R ₄ , n and m are defined in claim 1, except that R4 is not H, but n and m are not equal to 0.

50. The method of claim 49, wherein tributylphosphine and 1,1 ’- (azodicarbonyl) dipiperidine are used as the reactant, and where anhydrous benzene or anhydrous THF is used as the solvent.

51. A method of obtaining a compound of formula (I), which includes:

a) conversion of a functional group —OH of a compound of formula IV

where X, Y, Z and t are defined in clause 64, in the corresponding leaving group L, such as para-toluenesulfonate, methanesulfonate, halogen, triflate and the like, to obtain the compounds of formula VI

where X, Y, Z and t are defined in § 49, and L represents a leaving group such as para-toluenesulfonate, methanesulfonate, halogen, triflate and the like, and

b) the interaction of the compounds of formula VI

where X, Y, Z and t are defined in § 49, and L represents a leaving group, such as para-toluenesulfonate, methanesulfonate, halogen, triflate and the like, with a compound of formula V

where Q, Ar, R ₁ , R ₂ , R ₃ , R ₄ and m are defined in claim 1, except that m is not 0, to obtain a compound of formula I, where X, Y, Z, Q, Ar , R ₁ , R ₂ , R ₃ , R ₄ , n and m are defined in claim 1, except that R ₄ does not represent H, and n and m are not equal to 0.

52. The method according to § 51, where L is chlorine and where the reagent used in stage a) is triethylamine, anhydrous dichloromethane and methanesulfonyl chloride.

53. The method of claim 51, wherein L is chlorine and where the reagent used in step b) is potassium carbonate and sodium or potassium iodide, and where the solvent is acetone, and where the reaction temperature is a distillation temperature.

54. A pharmaceutical composition suitable for the treatment of type I diabetes, type II diabetes, reduced glucose tolerance, insulin resistance or obesity, comprising a compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, a mixture of stereoisomers, including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and an ACE (angiotensin converting enzyme) inhibitor.

55. The use of a compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, stereoisomers mixtures, including racemic mixtures, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and an ACE inhibitor (angiotensin-converting enzyme), to obtain a drug suitable for the treatment of type I diabetes, type II diabetes, reduced glucose tolerance, insulin resistance Does obesity.

56. A method for treating type I diabetes, type II diabetes, reduced glucose tolerance, insulin resistance or obesity, comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 1-36 or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable salt thereof MES, or any tautomeric forms, stereoisomers, mixtures of stereoisomers, including racemic mixtures, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and an ACE inhibitor (angiotens in-converting enzyme).

57. A pharmaceutical composition suitable for the treatment of type I diabetes, type II diabetes, reduced glucose tolerance, insulin resistance or obesity, comprising a compound according to any one of claims 1 to 36 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, a mixture of stereoisomers, including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and an agent that stimulates the release of insulin from β-glue OK, such as meglitinide, repaglinide or similar senaglinidu.

58. The use of a compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, stereoisomers mixtures, including racemic mixtures, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and an agent that stimulates the release of insulin from β-cells, such as meglitinide, like repaglinide or senaglinide to obtain a drug suitable for the treatment of type I diabetes, type diabetes II, reduced glucose tolerance, insulin resistance or obesity.

59. A method of treating type I diabetes, type II diabetes, decreased glucose tolerance, insulin resistance or obesity, comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 1-36 and an agent that stimulates the release of insulin from β-cells such as meglitinide, similar to repaglinide or senaglinide.

60. A pharmaceutical composition suitable for the treatment of type I diabetes, type II diabetes, decreased glucose tolerance, insulin resistance or obesity, comprising a compound according to any one of claims 1 to 36 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, a mixture of stereoisomers, including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and a biguanide like metformin.

61. The use of a compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, stereoisomers mixtures, including racemic mixtures, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and a biguanide like metformin to produce a medicament suitable for the treatment of type I diabetes, type II diabetes, reduced glucose tolerance, insulin resistance or obesity.

62. A method for treating type I diabetes, type II diabetes, reduced glucose tolerance, insulin resistance or obesity, comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 1-36 or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable salt thereof a solvate, or any tautomeric forms, stereoisomers, a mixture of stereoisomers, including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and a biguanide like metf rminu.

63. A pharmaceutical composition suitable for the treatment of type I diabetes, type II diabetes, decreased glucose tolerance, insulin resistance or obesity, comprising a compound according to any one of claims 1 to 36 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, a mixture of stereoisomers, including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and an HMG CoA inhibitor.

64. The use of a compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, stereoisomers mixtures, including racemic mixtures, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and an HMG CoA inhibitor for the manufacture of a medicament suitable for the treatment of type I diabetes, type II diabetes, decreased glucose tolerance, insulin resistance or obesity.

65. A method of treating type I diabetes, type II diabetes, decreased glucose tolerance, insulin resistance or obesity, comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 1-36 or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable salt thereof MES, or any tautomeric forms, stereoisomers, mixtures of stereoisomers, including racemic mixtures, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and an HMG CoA inhibitor.